Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of JNJ-39588146 in Heart Failure
NCT01120210Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Jun 2010
- Primary completion
- Sep 2011
- Modality
- Modified Peptides, Native Peptides
- Countries
- 4
01
Overview
A Phase 2 trial of stresscopin in heart failure (HF), sponsored by Johnson & Johnson. Started Jun 2010; status: completed.
02
Drugs
stresscopin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT01120210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01120210.